AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10356087 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh spinach, fresh broccoli, fresh romaine lettuce
Number of subjects: 11
Study 10356087 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh or cooked broccoli, fresh romaine lettuce with meals containing 30 or 45% energy as fat
Number of subjects: 11
Study 8966494 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplements (1.2 g of calcium and 800 IU of vitamin D3)
Number of subjects: 3270
Study 8966494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3270
Study 8403654 — intervention group
Group type: EXPERIMENTAL
Intervention: Debridement and intravenous antibiotics for four weeks
Number of subjects: 52
Study 8403654 — intervention group
Group type: COMPARATOR
Intervention: Debridement, gentamicin-polymethylmethacrylate (Septopal) beads, and perioperative broad-spectrum parenteral antibiotics
Number of subjects: 52
Study 4030862 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair followed by splinting in abduction
Number of subjects: 89
Study 4030862 — intervention group
Group type: COMPARATOR
Intervention: Repair followed by resting the arm at the side
Number of subjects: 89
Study 4030862 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision of the coraco-acromial ligament
Number of subjects: 89
Study 4030862 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients less than 60 years old
Number of subjects: 89
Study 4030862 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients over 60 years old
Number of subjects: 89
Study 30205658 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance followed by endurance training (ER, n = 12)
Number of subjects: 40
Study 30205658 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training followed by resistance training (RE, n = 12)
Number of subjects: 40
Study 30205658 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval resistance-endurance training (INT, n = 12)
Number of subjects: 40
Study 30205658 — intervention group
Group type: COMPARATOR
Intervention: Control group (Con, n = 12)
Number of subjects: 40
Study 30205658 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training within the SE, ES and INT groups
Number of subjects: 40
Study 27220350 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP with heated humidification
Number of subjects: 20
Study 27220350 — intervention group
Group type: COMPARATOR
Intervention: Conventional CPAP
Number of subjects: 20
Study 24607303 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazil nuts (20 g)
Number of subjects: 10
Study 24607303 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazil nuts (50 g)
Number of subjects: 10
Study 24607303 — intervention group
Group type: COMPARATOR
Intervention: Brazil nuts (0 g)
Number of subjects: 10
Study 24607303 — intervention group
Group type: COMPARATOR
Intervention: Brazil nuts (5 g)
Number of subjects: 10
Study 22781770 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track surgery
Number of subjects: 70
Study 22781770 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 70
Study 20462352 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin (6 mg/kg daily)
Number of subjects: 108
Study 18709519 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontrast helical computed tomography (CT) for diagnosis of ureterolithiasis
Number of subjects: 0
Study 18709519 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial management concepts including effective pain control
Number of subjects: 0
Study 15834081 — intervention group
Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03% combined with latanoprost 0.005% in case eyes
Number of subjects: 18
Study 15834081 — intervention group
Group type: COMPARATOR
Intervention: latanoprost 0.005% in control eyes
Number of subjects: 18
Study 12186576 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative-learning program
Number of subjects: 0
Study 12186576 — intervention group
Group type: COMPARATOR
Intervention: Social-contact program
Number of subjects: 0
Study 12186576 — intervention group
Group type: COMPARATOR
Intervention: Control (no classroom contact)
Number of subjects: 0
Study 10469695 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfundal route (Veress needle inserted through the uterine fundus)
Number of subjects: 100
Study 10469695 — intervention group
Group type: COMPARATOR
Intervention: Infra‐umbilical route
Number of subjects: 100
Study 8683548 — intervention group
Group type: EXPERIMENTAL
Intervention: Serratia marcescens strains isolated from contact lenses
Number of subjects: 12
Study 8683548 — intervention group
Group type: EXPERIMENTAL
Intervention: Serratia marcescens strains isolated from eyes and other sources
Number of subjects: 12
Study 8683548 — intervention group
Group type: EXPERIMENTAL
Intervention: Serratia marcescens strains from contact lenses
Number of subjects: 12
Study 1906363 — intervention group
Group type: EXPERIMENTAL
Intervention: RU486 (Mifepristone) and Misoprostol (orally active PGE1 synthetic derivative)
Number of subjects: 100
Study 1906363 — intervention group
Group type: COMPARATOR
Intervention: RU486 (Mifepristone) and Sulprostone (intramuscularly injected prostaglandin)
Number of subjects: 100
Study 6396248 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% crotamiton lotion
Number of subjects: 31
Study 6396248 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 31
Study 30813955 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anaesthesia (LA)
Number of subjects: 54
Study 30813955 — intervention group
Group type: COMPARATOR
Intervention: General Anaesthesia (GA)
Number of subjects: 54
Study 30845291 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + Amoxicillin + Metronidazole, each 500 mg, three times daily, for seven days (test group)
Number of subjects: 16
Study 30845291 — intervention group
Group type: COMPARATOR
Intervention: SRP + placebo for seven days (control group)
Number of subjects: 16
Study 26685701 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone (up to 40 mg/day)
Number of subjects: 76
Study 26685701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 26685701 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone
Number of subjects: 76
Study 24628408 — intervention group
Group type: EXPERIMENTAL
Intervention: Face Mask (FM) treatment
Number of subjects: 32
Study 24628408 — intervention group
Group type: EXPERIMENTAL
Intervention: Face Mask (FM) treatment with Rapid Maxillary Expansion (RME)
Number of subjects: 32
Study 24628408 — intervention group
Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 32
Study 22931974 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 59
Study 22931974 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 59
Study 21179724 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese drugs for benefiting‐qi, activating‐blood, dissolving phlegm and removing‐toxin (CDs) combined with basic therapy
Number of subjects: 56
Study 21179724 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy only (Control)
Number of subjects: 56
Study 17514701 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EA) with local anaesthetic
Number of subjects: 16
Study 15620437 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 360 mg/day for one year
Number of subjects: 106
Study 15620437 — intervention group
Group type: COMPARATOR
Intervention: Control group (age, sex, BMI matched)
Number of subjects: 106
Study 11879860 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive 3-day communication skills training course
Number of subjects: 160
Study 11879860 — intervention group
Group type: COMPARATOR
Intervention: Written feedback
Number of subjects: 160
Study 11879860 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study 10206573 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy
Number of subjects: 147
Study 10206573 — intervention group
Group type: EXPERIMENTAL
Intervention: Enucleation
Number of subjects: 147
Study 7615288 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) treatment
Number of subjects: 65
Study 2297261 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue spray (2 ml applied before thoracotomy closure)
Number of subjects: 28
Study 2297261 — intervention group
Group type: COMPARATOR
Intervention: Control (no fibrin glue)
Number of subjects: 28
Study 832923 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic subjects (Ss)
Number of subjects: 90
Study 832923 — intervention group
Group type: COMPARATOR
Intervention: Task motivated Ss
Number of subjects: 90
Study 832923 — intervention group
Group type: COMPARATOR
Intervention: Control Ss
Number of subjects: 90
Study 832923 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic Ss with high suggestibility
Number of subjects: 90
Study 832923 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic Ss responding to difficult task aspects
Number of subjects: 90
Study 31488259 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids (first line treatment)
Number of subjects: 93
Study 31488259 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (monotherapy or in association with steroids)
Number of subjects: 93
Study 31488259 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive treatment
Number of subjects: 93
Study 31488259 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of steroids with rituximab
Number of subjects: 93
Study 31488259 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 93
Study 30732945 — intervention group
Group type: EXPERIMENTAL
Intervention: FIPELS technique flap design
Number of subjects: 35
Study 30732945 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 35
Study 26746184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive SBP management (<140 mm Hg)
Number of subjects: 1310
Study 26746184 — intervention group
Group type: COMPARATOR
Intervention: Guideline-based SBP management (<180 mm Hg)
Number of subjects: 1310
Study 25730283 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine injection plus argon plasma coagulation (APC)
Number of subjects: 276
Study 25730283 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine injection plus soft coagulation using hemostatic forceps (HFSC)
Number of subjects: 276
Study 23523332 — intervention group
Group type: EXPERIMENTAL
Intervention: Injections during labor
Number of subjects: 22352
Study 21474498 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-based monitoring system (internet strategy)
Number of subjects: 95
Study 21474498 — intervention group
Group type: COMPARATOR
Intervention: conventional treatment
Number of subjects: 95
Study 19281920 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 80
Study 19281920 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 80
Study 17084960 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐blocker
Number of subjects: 90
Study 17084960 — intervention group
Group type: EXPERIMENTAL
Intervention: triple therapy (alpha‐blocker, anti‐inflammatory, and muscle relaxant)
Number of subjects: 90
Study 17084960 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 90
Study 15276394 — intervention group
Group type: EXPERIMENTAL
Intervention: Darusentan 10 mg
Number of subjects: 642
Study 15276394 — intervention group
Group type: EXPERIMENTAL
Intervention: Darusentan 25 mg
Number of subjects: 642
Study 15276394 — intervention group
Group type: EXPERIMENTAL
Intervention: Darusentan 50 mg
Number of subjects: 642
Study 15276394 — intervention group
Group type: EXPERIMENTAL
Intervention: Darusentan 100 mg
Number of subjects: 642
Study 15276394 — intervention group
Group type: EXPERIMENTAL
Intervention: Darusentan 300 mg
Number of subjects: 642
Study 15276394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 642
Study 11352981 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 polyunsaturated fatty acids (PUFA) for 6 weeks
Number of subjects: 0
Study 11352981 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐week n‐3 PUFA‐enriched diet
Number of subjects: 0
Study 11352981 — intervention group
Group type: COMPARATOR
Intervention: 1 mM of eicosapentaenoic acid
Number of subjects: 0
Study 11352981 — intervention group
Group type: COMPARATOR
Intervention: 1 mM of docosahexaenoic acid (DHA)
Number of subjects: 0
Study 11352981 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 PUFA
Number of subjects: 0
Study 9456068 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of 2,3 dimercapto‐1‐propane sulfonic acid (DMPS)
Number of subjects: 348
Study 9456068 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam removal
Number of subjects: 348
Study 9456068 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 348
Study 8197927 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 3286547 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic alpha-interferon (10 million units subcutaneously daily)
Number of subjects: 64
Study 3286547 — intervention group
Group type: COMPARATOR
Intervention: Systemic acyclovir (5 mg/kg body weight intravenously thrice daily)
Number of subjects: 64
Study 3286547 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic alpha-interferon
Number of subjects: 64
Study 3286547 — intervention group
Group type: COMPARATOR
Intervention: Systemic acyclovir
Number of subjects: 64
Study 31846024 — intervention group
Group type: EXPERIMENTAL
Intervention: Flags approach-based educational intervention
Number of subjects: 63
Study 31846024 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 63
Study 29748628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 20
Study 29748628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 28012835 — intervention group
Group type: EXPERIMENTAL
Intervention: low‐flu/val (10/20mg)
Number of subjects: 40
Study 28012835 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 26412349 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy alone without chemotherapy (for recurrence score of 0 to 10)
Number of subjects: 1626
Study 23679351 — intervention group
Group type: EXPERIMENTAL
Intervention: Motesanib 125 mg once daily (Arm A)
Number of subjects: 49
Study 23679351 — intervention group
Group type: EXPERIMENTAL
Intervention: Motesanib 75 mg twice daily, 14-days-on/7-days-off (Arm B)
Number of subjects: 49
Study 23679351 — intervention group
Group type: EXPERIMENTAL
Intervention: Motesanib 75 mg twice daily, 5-days-on/2-days-off (Arm C)
Number of subjects: 49
Study 20734448 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography (TTE)
Number of subjects: 52
Study 20734448 — intervention group
Group type: COMPARATOR
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 52
Study 19180923 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 1 microg/kg
Number of subjects: 120
Study 19180923 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 2 microg/kg
Number of subjects: 120
Study 19180923 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 3 microg/kg
Number of subjects: 120
Study 19180923 — intervention group
Group type: COMPARATOR
Intervention: vecuronium bromide 0.1 mg/kg (control group)
Number of subjects: 120
Study 19180923 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (I, II, III)
Number of subjects: 120
Study 16635694 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol (Lev) 1.25 mg
Number of subjects: 627
Study 16635694 — intervention group
Group type: COMPARATOR
Intervention: Racemic albuterol (Rac) 2.5 mg
Number of subjects: 627
Study 16635694 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol (Lev)
Number of subjects: 627
Study 16635694 — intervention group
Group type: COMPARATOR
Intervention: Racemic albuterol (Rac)
Number of subjects: 627
Study 12786700 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel (Restylane)
Number of subjects: 138
Study 12786700 — intervention group
Group type: COMPARATOR
Intervention: Bovine collagen (Zyplast)
Number of subjects: 138
Study 12786700 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 138
Study 10982117 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive video plus a booklet
Number of subjects: 393
Study 10982117 — intervention group
Group type: COMPARATOR
Intervention: Booklet alone
Number of subjects: 393
Study 8973725 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-H2 treatment
Number of subjects: 68
Study 8973725 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 68
Study 1729971 — intervention group
Group type: EXPERIMENTAL
Intervention: Dantrolene Sodium (Dantrium), 200 mg per day
Number of subjects: 31
Study 1729971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 6385051 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation-only
Number of subjects: 0
Study 6385051 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O only
Number of subjects: 0
Study 6385051 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation with N2O
Number of subjects: 0
Study 6385051 — intervention group
Group type: COMPARATOR
Intervention: Room air-control
Number of subjects: 0
Study 31025470 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Rehabilitation (CBR)
Number of subjects: 39
Study 31025470 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 39
Study 28752800 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT) for 24 weeks
Number of subjects: 35
Study 28752800 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group (habitual lifestyle for 24 weeks)
Number of subjects: 35
Study 26948290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 24953493 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral symptomatic plaques
Number of subjects: 39
Study 24953493 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic plaques
Number of subjects: 39
Study 24953493 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic plaques
Number of subjects: 39
Study 22052188 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-speak SART
Number of subjects: 72
Study 22052188 — intervention group
Group type: EXPERIMENTAL
Intervention: Word SART
Number of subjects: 72
Study 22052188 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-speak task (Experiment 2)
Number of subjects: 72
Study 22052188 — intervention group
Group type: EXPERIMENTAL
Intervention: Word task (Experiment 2)
Number of subjects: 72
Study 19559376 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency treatment for renal colic
Number of subjects: 0
Study 17574954 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands
Number of subjects: 36
Study 17574954 — intervention group
Group type: COMPARATOR
Intervention: Device (original hard rubber tip)
Number of subjects: 36
Study 17574954 — intervention group
Group type: EXPERIMENTAL
Intervention: Device (soft molded rubber tip)
Number of subjects: 36
Study 17574954 — intervention group
Group type: COMPARATOR
Intervention: Hands (grade I to grade III mobilization)
Number of subjects: 36
Study 16234962 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with teriparatide plus raloxifene
Number of subjects: 137
Study 16234962 — intervention group
Group type: COMPARATOR
Intervention: Teriparatide alone
Number of subjects: 137
Study 12088118 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene 40 mg/d
Number of subjects: 1354
Study 12088118 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg/d
Number of subjects: 1354
Study 10370664 — intervention group
Group type: EXPERIMENTAL
Intervention: HAIC (+) group (received HAIC after radical hepatectomy)
Number of subjects: 135
Study 10370664 — intervention group
Group type: COMPARATOR
Intervention: HAIC (−) group (received radical hepatectomy alone)
Number of subjects: 135
Study 7727813 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate free, variable chloride dialysate
Number of subjects: 6
Study 7727813 — intervention group
Group type: COMPARATOR
Intervention: Standard acetate containing dialysate
Number of subjects: 6
Study 2127424 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily x 5 bolus recombinant gamma-interferon
Number of subjects: 30
Study 2127424 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion x 5 days recombinant gamma-interferon
Number of subjects: 30
Study 6995221 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 75
Study 6995221 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa and dopa-decarboxylase inhibitor
Number of subjects: 75
Study 6995221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 31557693 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT) + Treatment As Usual (TAU)
Number of subjects: 292
Study 31557693 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 292
Study 29099048 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate (LC) breakfast
Number of subjects: 16
Study 29099048 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate (HC) breakfast
Number of subjects: 16
Study 25573533 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 100 mg b.i.d. (intermittent dosing; capsules) plus gemcitabine 600 mg/m(2)
Number of subjects: 66
Study 25573533 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone (1000 mg/m(2))
Number of subjects: 66
Study 24139930 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 128
Study 21498427 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline with adherence support (AS; n = 36)
Number of subjects: 72
Study 21498427 — intervention group
Group type: COMPARATOR
Intervention: Varenicline with standard care (C; n = 36)
Number of subjects: 72
Study 21498427 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (both groups)
Number of subjects: 72
Study 19376585 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) 1.25 mg
Number of subjects: 150
Study 19376585 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) 1.25 mg and intravitreal triamcinolone (IVT) 2 mg
Number of subjects: 150